Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2

Deficiency of adenosine deaminase 2 (DADA2) is a monogenic form of systemic vasculopathy that often presents during early childhood. Linked to biallelic mutations in ADA2 (previously CECR1), DADA2 was initially described as a syndrome of recurrent fever, livedo racemosa, early-onset strokes, and peripheral vasculopathy that resembles polyarteritis nodosum. However, the wide spectrum of clinical findings and heterogeneity of disease, even among family members with identical mutations, is increasingly recognized. Evidence of systemic inflammation and vasculopathy is not uniformly present in DADA2 patients and some can remain asymptomatic through adulthood. Humoral immunodeficiency characterized by low immunoglobulin levels and increased risk of infection is another common feature of DADA2. Variable cytopenias including pure red cell aplasia that mimics Diamond-Blackfan anemia can also be primary manifestations of DADA2. How defects in a single gene translate into these heterogeneous presentations remains to be answered. In this review, we will summarize lessons learned from the pleiotropic clinical manifestations of DADA2.

[1]  S. Ozen,et al.  Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. , 2019, Journal of neuroradiology. Journal de neuroradiologie.

[2]  Todd W. Lyons,et al.  Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. , 2018, The Journal of allergy and clinical immunology.

[3]  K. Heimdal,et al.  A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience , 2018, European Journal of Human Genetics.

[4]  S. Mustjoki,et al.  ADA2 deficiency: Clonal lymphoproliferation in a subset of patients , 2018, The Journal of allergy and clinical immunology.

[5]  S. Holland,et al.  Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. , 2017, Blood.

[6]  M. Hershfield,et al.  Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders , 2017, Current Rheumatology Reports.

[7]  W. Schmidt,et al.  Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation , 2017, Pediatric Rheumatology.

[8]  V. Lougaris,et al.  Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood , 2017, Arthritis & rheumatology.

[9]  J. Kros,et al.  CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma , 2017, Oncogene.

[10]  G. Damonte,et al.  ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study , 2017, Annals of the rheumatic diseases.

[11]  A. Zavialov,et al.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells , 2017, Cellular and Molecular Life Sciences.

[12]  C. Kuhl,et al.  Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency , 2016, Neuropediatrics.

[13]  Masayuki Sakurai,et al.  Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases , 2016, Genes.

[14]  M. Hershfield,et al.  Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency. , 2016, The Journal of pediatrics.

[15]  F. Penco,et al.  Monogenic polyarteritis: the lesson of ADA2 deficiency , 2016, Pediatric Rheumatology.

[16]  S. Holland,et al.  Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. , 2016, The Journal of allergy and clinical immunology.

[17]  Y. Crow,et al.  ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters , 2016, RMD Open.

[18]  J. Beckmann,et al.  IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. , 2016, The Journal of allergy and clinical immunology.

[19]  N. Klein,et al.  Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases , 2016, Arthritis & rheumatology.

[20]  H. Cao,et al.  Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency , 2016, Journal of Clinical Immunology.

[21]  Qing Zhou,et al.  Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis , 2016, Journal of Neurology.

[22]  R. Krance,et al.  Adenosine Deaminase 2 Deficiency As a Cause of Pure Red Cell Aplasia Mimicking Diamond Blackfan Anemia , 2015 .

[23]  A. Zavialov,et al.  Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa. , 2015, JAMA dermatology.

[24]  P. Nederkoorn,et al.  Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations , 2015, Pediatric Rheumatology.

[25]  P. Seeburg,et al.  RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself , 2015, Science.

[26]  S. Özen,et al.  A case series of adenosine deaminase 2 deficient patients emphasizing treatment and genotype-phenotype correlations , 2015, The Journal of Rheumatology.

[27]  C. Wouters,et al.  Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency , 2015, The Journal of allergy and clinical immunology.

[28]  A. Liston,et al.  Mutant ADA2 in vasculopathies. , 2014, The New England journal of medicine.

[29]  T. Walsh,et al.  Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. , 2014, The New England journal of medicine.

[30]  J. Mullikin,et al.  Early-onset stroke and vasculopathy associated with mutations in ADA2. , 2014, The New England journal of medicine.

[31]  D. Zurakowski,et al.  Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study , 2013, Pediatric Rheumatology.

[32]  John H Livingston,et al.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.

[33]  N. Glaichenhaus,et al.  Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages , 2010, Journal of leukocyte biology.

[34]  P. Merkel,et al.  Genetics of vasculitis , 2010, Current opinion in rheumatology.

[35]  A. Zavialov,et al.  Structural Basis for the Growth Factor Activity of Human Adenosine Deaminase ADA2*♦ , 2010, The Journal of Biological Chemistry.

[36]  P. Lamprecht,et al.  Antineutrophil cytoplasmic antibody-associated vasculitis: autoinflammation, autodestruction and autoimmunity--key to new therapies. , 2008, Trends in immunology.

[37]  Pál Pacher,et al.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.

[38]  Takaya Yamamoto,et al.  Human plasma adenosine deaminase 2 is secreted by activated monocytes , 2006, Biological chemistry.

[39]  P Woo,et al.  EULAR/PReS endorsed consensus criteria* for the classification of childhood vasculitides , 2005, Annals of the rheumatic diseases.

[40]  A. Zavialov,et al.  Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. , 2005, The Biochemical journal.

[41]  T. Southwood,et al.  Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins , 2002, The Lancet.

[42]  P. Bryant,et al.  Adenosine deaminase-related growth factors stimulate cell proliferation in Drosophila by depleting extracellular adenosine , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Birren,et al.  Analysis of the cat eye syndrome critical region in humans and the region of conserved synteny in mice: a search for candidate genes at or near the human chromosome 22 pericentromere. , 2001, Genome research.

[44]  B. Roe,et al.  The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. , 2000, Genomics.

[45]  H. Shiraishi,et al.  Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum. , 1990, Analytical biochemistry.

[46]  D. Pirino,et al.  Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2. , 1989, Panminerva medica.

[47]  F. Martiniuk,et al.  Differential expression of adenosine deaminase isozymes in acute leukemia. , 1988, Blood.

[48]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[49]  E. Ben-Chetrit,et al.  Vasculitis in the autoinflammatory diseases , 2017, Current opinion in rheumatology.

[50]  H. Ozdogan,et al.  Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency , 2017, Rheumatology International.

[51]  A. Wakhlu,et al.  Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes , 2017, Rheumatology International.

[52]  R. Petty,et al.  Chapter 32 – Vasculitis and Its Classification , 2016 .

[53]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[54]  R. Sarı,et al.  Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[55]  B. Pollara,et al.  Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. , 1978, Proceedings of the National Academy of Sciences of the United States of America.